This study provides novel insights into the potential therapeutic target and strategy for attenuating the progression of ccRCC by revealing the role of VHL in regulating chronic inflammation within the LCN-2–ferroptosis pathway. This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.